XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table summarizes revenue by product:
 
Three Months Ended
March 31,
 
2019
 
2018
 
United States (U.S.) (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity®
$
665.6

$
214.1

$
879.7

 
$
528.2

$
150.1

$
678.3

Humalog®
448.6

282.2

730.8

 
504.1

287.6

791.7

Forteo®
125.9

187.0

312.9

 
122.1

191.1

313.2

Humulin®
201.3

96.4

297.7

 
221.6

104.3

325.9

Basaglar®
198.2

53.2

251.4

 
126.7

39.3

166.0

Jardiance
125.2

78.4

203.6

 
95.0

56.0

151.0

Trajenta
47.4

84.6

131.9

 
54.1

87.0

141.1

Other Endocrinology
61.7

60.3

122.1

 
64.1

67.5

131.5

Total Endocrinology
1,873.9

1,056.2

2,930.1

 
1,715.9

982.9

2,698.7

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta®
281.8

217.4

499.2

 
245.3

254.3

499.6

Cyramza®
75.1

123.2

198.3

 
68.3

115.3

183.6

Erbitux®
113.3

5.1

118.4

 
121.3

28.3

149.6

Verzenio®
93.5

15.9

109.4

 
29.7


29.7

Other Oncology
30.2

57.3

87.4

 
45.6

48.4

94.1

Total Oncology
593.9

418.9

1,012.7

 
510.2

446.3

956.6

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta®
10.3

153.8

164.1

 
12.2

157.3

169.6

Zyprexa®
9.3

97.9

107.2

 
8.8

113.8

122.6

Strattera®
1.5

64.7

66.2

 
46.9

83.7

130.7

Emgality®
12.2

2.1

14.2

 



Other Neuroscience
17.8

23.5

41.4

 
23.3

26.7

49.8

Total Neuroscience
51.1

342.0

393.1

 
91.2

381.5

472.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
180.8

71.7

252.5

 
111.2

35.3

146.5

Other Immunology
6.4

75.7

82.2

 

32.2

32.2

Total Immunology
187.2

147.4

334.7

 
111.2

67.5

178.7

 
 
 
 
 
 
 
 
Other
 
 
 
 
 
 
 
Cialis®
143.2

164.9

308.2

 
313.4

182.0

495.4

Other
41.5

72.0

113.4

 
53.7

108.0

161.7

Total Other
184.7

236.9

421.6

 
367.1

290.0

657.1

Revenue
$
2,890.8

$
2,201.4

$
5,092.2

 
$
2,795.6

$
2,168.2

$
4,963.8

Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.


The following table summarizes revenue by geographical area:
 
Three Months Ended
March 31,
 
2019
 
2018
Revenue—to unaffiliated customers (1):
 
 
 
United States (2)
$
2,890.8

 
$
2,795.6

Europe
900.3

 
864.2

Japan
543.7

 
537.0

Other foreign countries
757.4

 
767.1

Revenue
$
5,092.2

 
$
4,963.8

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
(2) U.S. revenue includes revenue in Puerto Rico.
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
March 31,
 
2019
 
2018
Net product revenue
$
4,692.3

 
$
4,605.9

Collaboration and other revenue (1)
399.9

 
357.9

Revenue
$
5,092.2

 
$
4,963.8

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $35.5 million and $50.1 million during the three months ended March 31, 2019 and 2018, respectively.
Schedule of amounts recorded for contract liabilities
The following table summarizes contract liability balances:
 
March 31, 2019
 
December 31, 2018
Contract liabilities
$
286.4

 
$
298.7